{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:26:43Z","timestamp":1777991203372,"version":"3.51.4"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>We describe a 6-week-old male-term infant with a pulmonary aspergilloma diagnosed following lobectomy for suspected pleuropulmonary blastoma, with characteristic histopathologic findings and <jats:italic toggle=\"yes\">Aspergillus<\/jats:italic> detected by polymerase chain reaction. Intensive testing did not reveal primary or secondary immunodeficiency. During 5 weeks treatment with voriconazole including regular therapeutic drug monitoring and dose adjustment, a level in the target range was never achieved. When the patient developed photosensitivity, treatment was stopped without relapse over 12 months follow-up. Voriconazole dosing is notoriously challenging in children. We review the cumulative published experience with voriconazole use in infants to highlight even greater difficulty in infants. Pulmonary aspergillosis is typically a disease affecting immunocompromised or critically ill patients. In children, it is well described in those with chronic granulomatous disease (CGD) as a complication of immunosuppressive antineoplastic chemotherapy and rarely in extremely- or very-low birthweight premature neonatal intensive care patients. The diagnosis is extremely rare in children without underlying risk factors. To our knowledge, this is the first report of a pulmonary aspergilloma in an immunocompetent infant.<\/jats:p>","DOI":"10.1097\/inf.0000000000002959","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T15:46:58Z","timestamp":1614008818000},"page":"227-230","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Rare Infant Case of Pulmonary Aspergilloma Highlighting Common Challenges With Voriconazole Dosing"],"prefix":"10.1097","volume":"40","author":[{"given":"Yara-Natalie","family":"Abo","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, The Royal Children\u2019s Hospital Melbourne"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Gwee","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, The Royal Children\u2019s Hospital Melbourne"},{"name":"Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia"},{"name":"Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Osowicki","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, The Royal Children\u2019s Hospital Melbourne"},{"name":"Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia"},{"name":"Tropical Diseases Research Groups, Murdoch Children\u2019s Research Institute, Melbourne, Victoria, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"key":"R1-20250615","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jiac.2019.06.011","article-title":"Infantile Aspergillus fumigatus ventriculitis successfully treated with monitoring of plasma and cerebrospinal fluid voriconazole concentration level.","volume":"26","author":"Furudate","year":"2020","journal-title":"J Infect Chemother"},{"key":"R2-20250615","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/INF.0000000000002073","article-title":"Voriconazole treatment for an infant with intractable Candida glabrata meningitis.","volume":"37","author":"Tsakiri","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"R3-20250615","first-page":"54","article-title":"Voriconazole: poor oral bioavailability and possible renal toxicity in an infant with invasive aspergillosis.","volume":"23","author":"Walldorf","year":"2018","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R4-20250615","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/INF.0000000000001136","article-title":"Primary cutaneous Aspergillosis in a preterm infant.","volume":"35","author":"Frick","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R5-20250615","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/phar.1829","article-title":"An optimized voriconazole dosing strategy to achieve therapeutic serum concentrations in children younger than 2 years old.","volume":"36","author":"Zembles","year":"2016","journal-title":"Pharmacotherapy"},{"key":"R6-20250615","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1592\/phco.2005.25.6.893","article-title":"Intravenous voriconazole therapy in a preterm infant.","volume":"25","author":"Muldrew","year":"2005","journal-title":"Pharmacotherapy"},{"key":"R7-20250615","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/INF.0b013e31824acc33","article-title":"Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.","volume":"31","author":"Doby","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R8-20250615","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10096-010-1079-8","article-title":"Voriconazole plasma levels in children are highly variable.","volume":"30","author":"Spriet","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R9-20250615","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/INF.0b013e318204d227","article-title":"Impact of therapeutic drug monitoring of voriconazole in a pediatric population.","volume":"30","author":"Br\u00fcggemann","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R10-20250615","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/01.inf.0000258698.98370.89","article-title":"Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.","volume":"26","author":"Santos","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R11-20250615","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.jp.7211532","article-title":"Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight.","volume":"26","author":"Frankenbusch","year":"2006","journal-title":"J Perinatol"},{"key":"R12-20250615","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1097\/01.inf.0000095167.38306.76","article-title":"Voriconazole serum concentrations in an infant treated for Trichosporon beigelii infection.","volume":"22","author":"Maples","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"R13-20250615","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1086\/514717","article-title":"Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life.","volume":"27","author":"Groll","year":"1998","journal-title":"Clin Infect Dis"},{"key":"R14-20250615","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.cmi.2019.05.019","article-title":"ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children.","volume":"25","author":"Warris","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"R15-20250615","first-page":"53","article-title":"A fatal case of congenital pulmonary airway malformation with aspergillosis in an adult.","volume":"7","author":"Enuh","year":"2014","journal-title":"Int Med Case Rep J"},{"key":"R16-20250615","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1746-1596-7-37","article-title":"Congenital cystic adenomatoid malformation of lung in adults: 2 rare cases report and review of the literature.","volume":"7","author":"Feng","year":"2012","journal-title":"Diagn Pathol"},{"key":"R17-20250615","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/INF.0000000000000360","article-title":"Aspergilloma caused by Aspergillus versicolor.","volume":"33","author":"Kane","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R18-20250615","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/ppul.21538","article-title":"Aspergilloma in a patient with an occult congenital pulmonary airway malformation.","volume":"47","author":"Yonker","year":"2012","journal-title":"Pediatr Pulmonol"},{"key":"R19-20250615","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America.","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"R20-20250615","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"R21-20250615","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/mmy\/myz006","article-title":"Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients.","volume":"57","author":"Lempers","year":"2019","journal-title":"Med Mycol"},{"key":"R22-20250615","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/2047-783X-16-4-139","article-title":"Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature.","volume":"16","author":"Sandherr","year":"2011","journal-title":"Eur J Med Res"},{"key":"R24-20250615","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology\u2013drug disposition, action, and therapy in infants and children.","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"key":"R25-20250615","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/pbc.22451","article-title":"Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age.","volume":"54","author":"Shima","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R26-20250615","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/jpids\/pix022","article-title":"Voriconazole dosing in children younger than 3 years undergoing cancer chemotherapy or hematopoietic stem cell transplantation.","volume":"7","author":"Yan","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R27-20250615","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ijantimicag.2016.11.028","article-title":"Dose optimisation of voriconazole with therapeutic drug monitoring in children: a single-centre experience in China.","volume":"49","author":"Liu","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R28-20250615","doi-asserted-by":"crossref","first-page":"e01194","DOI":"10.1128\/AAC.01194-17","article-title":"Pharmacokinetic modeling of voriconazole to develop an alternative dosing regimen in children.","volume":"62","author":"Gastine","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:02:21Z","timestamp":1750003341000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002959","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,8]]}}}